DOI: 10.14704/nq.2019.17.3.2010

Focal Dystonia and Botulinum Toxin: Our Experience with IncobotulinumtoxinA

Marinella Tomaselli, Leonello Tacconi, Giulia Mazzon, Paolo Manganotti

Abstract


Botulinum toxin type A (BTX-A) represent the gold standard therapy for focal dystonia and related hyperkinetic movement disorders. The main advantages of this method are low rate of complications, reversibility and efficacy in reducing spastic hypertonia or abnormal movements. The treatment is safe but it needs to be repeated periodically and some patients do not obtain effective control of the symptoms due to the onset of secondary immune resistance. For this reason we have selected 45 cases already in treatment with botulinum toxin that have been switched to incobotulinumtoxinA. At a median follow up of 8 months the greatest part of the patients, twenty-six (57.7%) remained clinically unchanged; fourteen (31.1%) had a significant clinical improvement and five (11.1%) worsened. We did not observe any general or injection site complications.

Keywords


focal dystonia, botulinum toxin; hemifacial spasm; immune response

Full Text:

PDF

References


Albanese A, Bathia K, Bressman SB, Delong MR, Fahn S. Phenomenology and classification of dystonia: a consensus update. Movement disorders 2013; 28(7): 863-873.

Albanese A, Asmus F, Bhatia KP, Elia AE, Elibol B, Filippini G, Gasser T, Krauss JK, Nardocci N, Newton A., Valls-Sole J. EFNS guidelines on diagnosis and treatment of primary dystonias. European Journal Neurology 2011; 18: 5-18.

Anderson RL, Patel BC, Holds JB, Jordan DR, Blepharospam: past present and future. Ophthalmology Plastic Reconstructive Surgery 1998; 14: 305-317

Carli L, Montecucco C, Rossetto O. Assay of diffusion of different botulinum neurotoxin type a formulations injected in the mouse leg. Muscle & Nerve: Official Journal of the American Association of Electrodiagnostic Medicine. 2009; 40(3): 374-80.

Costa J, Espírito‐Santo CC, Borges AA, Ferreira J, Coelho MM, Moore P, Sampaio C. Botulinum toxin type A therapy for blepharospasm. Cochrane Database of Systematic Reviews. 2004; 2.

De Paiva A, Meunier FA, Molgo J, Aoki KR, Dolly JO. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Procedure National Academic Sciences, USA 1999; 96: 3200-3205.

Dressler D, Clinical presentation and management of antibody-induced failure of botulinum toxin therapy. Movement Disorders 2004; 19: S92-S100.

Dressler D, Benecke R, Bigalke H. Botulinum toxin type B (neurobloc) in patients with botulinum toxin tuype A antibody-induced therapy failure. Journal of Neurolology 2017; 250: 967-969.

Dressler D. Clinical features of antibody-induced complete secondary failure of botulinum toxin therapy. European Neurology 2002; 48: 26-29.

Green KE, Rastall D, Eggenberger E. Treatmnt of blepharospasm/hemifacial spasm. Current Treatment Options Neurology 2017; 19: 41.

Jankovic J, Tsui J, Bergeron C. Prevalence of cervical dystonia and spasmodic torticollis in the United States general population. Parkinsonism & Related Disorders 2007; 13(7): 411-416.

Jost WH, Brumel J, Grafe S. Botulinum neurotoxin type A free of complexing proteins (Xeomin) in focal Dystonia. Drugs 2007; 67: 669-683.

Kerscher M, Maack M, Reuther T, Kruger N. Diffusion characteristics of two different neurotoxins in patients with symmetric forehead lines. Journal American Academy Dermatology 2007; 56: AB199.

Kessler KR and Benecke R. The EBD test - a clinical test for the detection of antibodies to botulinum toxin type A. Movements Disorders 1997; 12: 95-99.

Marsh WA, Monroe DM, Brin MF, Gallagher CJ. Systematic review and meta-analysis of the duration of clinical effect of onabotulinumtoxinA in cervical dystonia. BMC Neurology 2014; 14: 91.

Matak I and Lackowic Z. Botulinum toxin type A: brain and pain. Progress in Neurobiology 2014; 119-120: 39-59.

Naumann M, Carruthers A, Carruthers J. Meta Analysis of neutralizing antibody conversion with onabotulinumtoxin (Botox) across multiple indications. Movement Disorders 2010; 25: 2211-2218.

Odergren T, Hjaltason H, Kaakkola S, Solders G, Hanko J, Fehling C. A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cevical dystonia. Journal Neurology Neurosurgery and Psychiatyry 1998; 64: 6-12.

Prager W, Prager W, Wissmuller E, Kollhorst B, Boer A, Zschocke L. Treatment of crow’s feet with two different botulinum toxin type A preparations in split-face technique. Hautarzt 2011; 62: 375-379.

Ranoux D, Gury C, Fondarai J, Mas JL, Zuber M. Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia. Journal Neurology Neurosurgery and psicgiatry 2002; 72: 459-462.

Roggenkamper P, Jost WH, Bihari K, Comes G, Grafe S. Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospsasm. Journal of Neural Trasmission 2006; 113: 303-312.

Sankhala C, Jankovic J, Duane D. Variability of the immunologic and clinical response in dystonic patients immunoresistant to botulinum toxin injections. Movement Disorders 1998; 13: 150-154.

Sanpaio C, Ferreira JJ, Simoes F, Rosas MJ, Magalhaes M, Correia AP. DYSPOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the effcicacy and tolerability of two formulations of botulinum toxin type A-Dysport and Botox- assuming a ratio of 4:1. Movement Disorders 1997;12: 1013-1018.

Santamato A, Ranieri M, Panza F, Frisardi V, Micello MF, Filoni S. Effectiveness of switching therapy from complexing protein containing botulinum toxin type A to a formulation with low immunogenicity in spasticity after stroke: a case report. Journal Rehabilitation Medicine 2012; 44: 795-797.

Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Journal Pediatric Ophtalmology Strabismus 1980; 17: 21-25.

Steeves TD, Day L, Dykeman J, Jette N, Pringsheim T. The prevalence of primary distonia: a systematic review and meta-analysis. Movement Disorders 2012; 27(14): 1789-1796.

Vitek JL. Pathophysiology of dystonia: a neuronal model. Movement Disorders 2002; 17: S49-S62.


Supporting Agencies





| NeuroScience + QuantumPhysics> NeuroQuantology :: Copyright 2001-2019